Globant and MIT Technology Review Reveal Rapid Adoption of Agentic AI in Pharma Industry, Highlighting $100 Billion Growth Opportunity

Reuters
2025/10/14
<a href="https://laohu8.com/S/GLOB">Globant</a> and MIT Technology Review Reveal Rapid Adoption of Agentic AI in Pharma Industry, Highlighting $100 Billion Growth Opportunity

Globant SA, in partnership with MIT Technology Review Insights, has released a new industry report titled "Transforming Commercial Pharma with Agentic AI," highlighting rapid adoption of agentic AI across the pharmaceutical sector. Based on a survey of 250 senior executives from nine countries, the study finds that three quarters of global pharma organizations are piloting or deploying agentic AI solutions. Early adopters are focusing on market intelligence, patient support, compliance, and data integration to capture over $100 billion in annual growth opportunities. The report emphasizes the importance of strong data foundations, with 84% of respondents prioritizing data standardization and integration. Industry leaders stress the need to embed agentic AI into core business processes, ensure compliance, and maintain clear human oversight for critical decision points.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Globant SA published the original content used to generate this news brief via PR Newswire (Ref. ID: SP97486) on October 14, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10